Back to Search Start Over

MTBVAC induces superior antibody titers and IgG avidity compared to BCG vaccination in non-human primates

Authors :
Marco Polo Peralta-Álvarez
Keya Downward
Andrew White
Hugo Redondo Azema
Laura Sibley
Charlotte Sarfas
Alexandra Morrison
Mike Dennis
Delia Diaz-Santana
Stephanie A. Harris
Shuailin Li
Eugenia Puentes
Nacho Aguilo
Carlos Martin
Sally Sharpe
Helen McShane
Rachel Tanner
Source :
npj Vaccines, Vol 9, Iss 1, Pp 1-10 (2024)
Publication Year :
2024
Publisher :
Nature Portfolio, 2024.

Abstract

Abstract The only currently licensed vaccine against tuberculosis (TB), Bacille Calmette Guérin (BCG), is insufficient to control the epidemic. MTBVAC is a live attenuated strain of Mycobacterium tuberculosis (M.tb) and is one the most advanced TB vaccine candidates in the pipeline. It is more efficacious than BCG in preclinical models including non-human primates (NHPs), and has demonstrated safety and immunogenicity in human populations. To better understand the immune mechanisms underlying the superior efficacy conferred by MTBVAC, we characterized M.tb-specific antibody responses in NHPs vaccinated with either BCG or MTBVAC. MTBVAC vaccination induced higher titers of IgG, IgM and IgA, and higher avidity IgG compared with BCG vaccination. IgG avidity correlated with protection following M.tb challenge in the same animals, validating the association previously reported between this measure and protection in the context of intravenous BCG vaccination, suggesting that IgG avidity may represent a relevant marker or correlate of protection from TB.

Details

Language :
English
ISSN :
20590105
Volume :
9
Issue :
1
Database :
Directory of Open Access Journals
Journal :
npj Vaccines
Publication Type :
Academic Journal
Accession number :
edsdoj.2d65dc12fc6546f0b6600b34a9dd124b
Document Type :
article
Full Text :
https://doi.org/10.1038/s41541-024-01009-5